Screening Immunomodulators To Skew the Antigen-Specific Autoimmune Response

Area of Science:

• Immunology
• Pharmacology
• Autoimmune Diseases

Background:

• Current autoimmune disease treatments cause nonspecific immunosuppression, increasing risks.
• Antigen-specific immune tolerance offers a safer alternative to reverse autoimmunity.
• Identifying immunomodulators that induce antigen-specific tolerance has been challenging.

Purpose of the Study:

• To develop an ex vivo screening method for identifying immunomodulators that induce antigen-specific immune tolerance.
• To investigate if certain immunomodulators can modify antigen-specific immune responses in splenocytes from mice with experimental autoimmune encephalomyelitis (EAE).

Main Methods:

• Splenocytes from EAE mice were cultured with autoantigens and various immunomodulatory compounds.
• Antigen-specific immune responses, including cytokine profiles and T-cell populations, were analyzed after antigen rechallenge.
• The effect of dexamethasone on immune cell populations and cytokine production was specifically examined.

Main Results:

• Dexamethasone was the only compound that significantly modified the antigen-specific immune response.
• Dexamethasone skewed the cytokine response and decreased T-cell populations at a relevant in vivo dose.
• This indicates dexamethasone's potential to induce markers of immune tolerance.

Conclusions:

• Antigen-educated EAE splenocytes provide a viable ex vivo screen for identifying compounds that skew antigen-specific immune responses.
• This approach can be extended to antigen-educated cells from other autoimmune diseases or human tissues.
• Dexamethasone shows promise in modulating immune responses for potential autoimmune disease therapies.